HEPCLUDEX (Gilead Sciences Pty Ltd)
Product name
HEPCLUDEX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
160 (255 working days)
Active ingredients
bulevirtide acetate
Registration type
NCE/NBE
Indication
HEPCLUDEX is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.